Please login to the form below

Not currently logged in
Email:
Password:

Votrient receives conditional EU authorisation

GlaxoSmithKline's renal cell cancer drug, Votrient, has received conditional marketing authorisation in the EU

GlaxoSmithKline (GSK) has announced that its renal cell cancer drug, Votrient (pazopanib) has been granted conditional marketing authorisation by the European Commission.

As part of these conditions, GSK will provide data from ongoing clinical studies before full authorisation is granted.

Votrient is intended for use in the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

The drug was previously recommended by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in April 2010.

The committee found a “favourable benefit to risk balance” with the drug, though proposed it should only be initiated by a physician experienced in the administration of anti-cancer agents.

The positive recommendation was a revision of an earlier negative one. The decision to change the recommendation followed the removal of Votrient from the EMA's community register of orphan medicinal products by GSK.

A drug can only be on the register if is intended for the diagnosis, prevention or treatment of a condition affecting fewer than five per ten thousand persons in the EU or if it will carry a notable benefit for the treatment a serious or debilitating disease and is unlikely to be marketed without incentives.

Votrient was previously approved in the US by the Food and Drug Administration (FDA) in October 2009 as a treatment for patients with advanced RCC.

15th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics